David and Goliath: Small-molecule inhibitors of the ERK signaling pathway (shown) and their potential as novel antitumor agents are discussed in detail within this Minireview. Specifically, the direct and indirect inhibition of ERK through ATP-competitive and non-ATP-competitive modes of action is highlighted.
No takes yet. Share an insight, caveat, or question.
Yap et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: